The potential for clinical translation of the present findings is emphasized by a recent randomized controlled trial that investigated the effects of the Pde4 inhibitor ibudilast on relapse-remitting MS (Barkhof et al, 2010). This evidence concerns the gene PDE4A and myeloid sarcoma.